Related references
Note: Only part of the references are listed.Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic hepatitis C virus-infected patients
Tomoaki Nakajima et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis
Susanne Feder et al.
LIPIDS IN HEALTH AND DISEASE (2021)
Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk
Gaetano Santulli et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review
Ahmed Babiker et al.
CLINICAL CARDIOLOGY (2020)
Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 Ameliorates Liver Fibrosis via Mitigation of Intestinal Endotoxemia
Yanting Zou et al.
INFLAMMATION (2020)
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition
Arturo Cesaro et al.
BIOFACTORS (2020)
The Moral of Hepatic Fibrosis: Don't Always Believe Noninvasive Fibrosis Measurements
Masaru Enomoto et al.
DIGESTIVE DISEASES AND SCIENCES (2020)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Not Induced in Artificial Human Inflammation and Is Not Correlated with Inflammatory Response
Matthias Wolfgang Heinzl et al.
INFECTION AND IMMUNITY (2020)
Viral eradication restores normal iron status in chronic hepatitis C patients with abnormal iron studies
Yazan Hasan et al.
ANNALS OF HEPATOLOGY (2020)
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort
Elizabeth C. Verna et al.
JOURNAL OF HEPATOLOGY (2020)
Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis
Maria R. Emma et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2020)
Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination Real-world experience of a retrospective study
Juan Li et al.
MEDICINE (2020)
PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma
Silvano Fasolato et al.
JOURNAL OF CLINICAL MEDICINE (2020)
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Julius L. Katzmann et al.
FRONTIERS IN PHYSIOLOGY (2020)
Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury
Georg Peschel et al.
DIAGNOSTICS (2020)
EASL recommendations on treatment of hepatitis C: Final update of the series
Jean-Michel Pawlotsky et al.
JOURNAL OF HEPATOLOGY (2020)
Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C
Meng-Hsuan Kuo et al.
TZU CHI MEDICAL JOURNAL (2020)
PCSK9 inhibition and inflammation: A narrative review
Massimiliano Ruscica et al.
ATHEROSCLEROSIS (2019)
Ultrasound is highly specific in diagnosing compensated cirrhosis in chronic hepatitis C patients in real world clinical practice
Yi-Hao Yen et al.
MEDICINE (2019)
A new dawn for managing dyslipidemias: The era of ma-based therapies
C. Macchi et al.
PHARMACOLOGICAL RESEARCH (2019)
Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum
Meenu Rohini Rajan et al.
SCIENTIFIC REPORTS (2019)
Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis
David E. Kaplan et al.
GASTROENTEROLOGY (2019)
Changes in serum LDL, PCSK9 and microRNA-122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir
Tatsuki Ichikawa et al.
BIOMEDICAL REPORTS (2019)
Prevalence and Predictors of Cholesterol Screening, Awareness, and Statin Treatment Among US Adults With Familial Hypercholesterolemia or Other Forms of Severe Dyslipidemia (1999-2014)
Emily M. Bucholz et al.
CIRCULATION (2018)
PCSK9 From Basic Science Discoveries to Clinical Trials
Michael D. Shapiro et al.
CIRCULATION RESEARCH (2018)
Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A
Zhubing Li et al.
JOURNAL OF GENERAL VIROLOGY (2018)
Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma
Shu-Yein Ho et al.
SCIENTIFIC REPORTS (2018)
Adipokines in Liver Cirrhosis
Christa Buechler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Lipid Lowering Therapy and Circulating PCSK9 Concentration
Tsuyoshi Nozue
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2017)
Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism
Matteo Pirro et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2017)
Nutritional and Lipid Modulation of PCSK9: Effects on Cardiometabolic Risk Factors
Jacqueline A. Krysa et al.
JOURNAL OF NUTRITION (2017)
Low PCSK9 levels are correlated with mortality in patients with end-stage liver disease
Valentin Schlegel et al.
PLOS ONE (2017)
Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b
Daisuke Endo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Statins and the risk of cirrhosis in hepatitis B or C patients: a systematic review and dose-response meta-analysis of observational studies
Yaqin Wang et al.
ONCOTARGET (2017)
Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9
Anastasia Hyrina et al.
EBIOMEDICINE (2017)
Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients
Stefan Toth et al.
CARDIOLOGY AND THERAPY (2017)
Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C
Taisa Grotta Ragazzo et al.
CLINICS (2017)
Liver fat accumulation is associated with circulating PCSK9
Massimiliano Ruscica et al.
ANNALS OF MEDICINE (2016)
HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent PCSK9-Lipid Paradox
Payal Kohli et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes
Aarti Ramanathan et al.
PLOS ONE (2016)
Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment
Satoru Hashimoto et al.
PLOS ONE (2016)
Decreased PCSK9 expression in human hepatocellular carcinoma
Mamatha Bhat et al.
BMC GASTROENTEROLOGY (2015)
PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism
Simon H. Bridge et al.
JOURNAL OF HEPATOLOGY (2015)
Isolation and characterization of the circulating truncated form of PCSK9
Bomie Han et al.
JOURNAL OF LIPID RESEARCH (2014)
Hepatitis C Virus Stimulates Low-Density Lipoprotein Receptor Expression To Facilitate Viral Propagation
Gulam Hussain Syed et al.
JOURNAL OF VIROLOGY (2014)
Review and management of drug interactions with boceprevir and telaprevir
Jennifer J. Kiser et al.
HEPATOLOGY (2012)
Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C
Gowtham A. Rao et al.
GASTROENTEROLOGY (2011)
Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans
Lena Persson et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans
Jeffrey D. Browning et al.
JOURNAL OF LIPID RESEARCH (2010)
Hepatitis C Virus Infection and the Risk of Coronary Disease
Adeel A. Butt et al.
CLINICAL INFECTIOUS DISEASES (2009)
PCSK9 Impedes Hepatitis C Virus Infection In Vitro and Modulates Liver CD81 Expression
Patrick Labonte et al.
HEPATOLOGY (2009)
The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis
S. A. Mousavi et al.
JOURNAL OF INTERNAL MEDICINE (2009)
Proprotein convertase Subtilisin/Kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
Ahmed Zaid et al.
HEPATOLOGY (2008)
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
Paul Angulo et al.
HEPATOLOGY (2007)
Steatosis in chronic hepatitis C: Why does it really matter?
T Asselah et al.
GUT (2006)
Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease
A Lonardo et al.
GASTROENTEROLOGY (2004)
Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth
MA Casiraghi et al.
HEPATOLOGY (2004)
Share Paper
